Scott B. Ullem Sells 11,250 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

CFO Scott B. Ullem of Edwards Lifesciences Co. (NYSE:EW - Get Free Report) sold a total of 11,250 shares of the company’s stock on March 26th. These shares were sold at an average price of $70.87 each, resulting in a total transaction value of $797,287.50. After completing this sale, Ullem owns 30,387 shares of the company, which are valued at approximately $2,153,526.69. This latest transaction indicates a 27.02% decrease in his ownership stake.

On the same day, shares of Edwards Lifesciences were trading down by $0.12, reaching $71.12. The trading volume was around 3,487,871 shares, which is lower than the average volume of 4,618,976 shares. The company's stock has a 50-day simple moving average of $71.43 and a 200-day simple moving average of $70.45. The market capitalization of Edwards Lifesciences stands at $41.81 billion. The company's P/E ratio is at 10.20, and its PEG ratio is 4.82. Additionally, Edwards Lifesciences has a debt-to-equity ratio of 0.06, a quick ratio of 2.89, and a current ratio of 3.46. Over the past year, the company's stock has experienced a 52-week low of $58.93 and a high of $96.12.

Financial Performance

Edwards Lifesciences last reported its quarterly earnings on February 11th, revealing earnings per share of $0.59, which surpassed analysts' expectations of $0.55 by $0.04. The company boasts a return on equity of 19.40% and a net margin of 72.93%. Analysts forecast that the company will report earnings per share of 2.45 for the current fiscal year.

Analyst Insights

Recent analyst reports have shown varying opinions on Edwards Lifesciences' stock. Citigroup raised its price target on the stock from $81.00 to $83.00, maintaining a "buy" rating. Meanwhile, Piper Sandler increased their target from $70.00 to $73.00, giving it a "neutral" rating. Barclays raised their target from $88.00 to $90.00 with an "overweight" rating. Conversely, Wolfe Research downgraded the stock from "hold" to "strong sell." Currently, one analyst rates the stock as a sell, fourteen state a hold rating, and twelve recommend a buy. The average rating stands at "Hold," with an average price target of $79.95.

Institutional Activity

In recent months, several institutional investors have made changes to their holdings in Edwards Lifesciences. Crowley Wealth Management Inc. acquired a new stake valued at approximately $26,000, while Vega Investment Solutions also invested around $27,000 in new shares. Other institutions include Millstone Evans Group LLC, FSA Wealth Management LLC, and Migdal Insurance & Financial Holdings Ltd., with stakes ranging from $29,000 to $30,000. Currently, institutional investors own approximately 79.46% of Edwards Lifesciences stock.

Company Overview

Edwards Lifesciences Corporation specializes in products and technologies targeting structural heart disease and critical care monitoring, both in the United States and internationally. The company offers transcatheter heart valve replacement solutions for minimally invasive aortic valve replacements and repair products for mitral and tricuspid valve conditions under the Edwards SAPIEN and PASCAL PRECISION brands.

investment, CFO, stocks